PSTI

Pluristem Therapeutics Inc
1.00
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
1.00
Volume 0
Bid Price 0.99
Ask Price 1.05
News -
Day High

Low
0.95

52 Week Range

High
2.21

Day Low
Company Name Stock Ticker Symbol Market Type
Pluristem Therapeutics Inc PSTI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.00 19:00:00
Open Price Low Price High Price Close Price Prev Close
1.00 1.00
Trades Volume Avg Volume 52 Week Range
0 0 - 0.95 - 2.21
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.00 USD

Period:

Draw Mode:

Pluristem Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 32.35M 32.35M 30.62M $ - $ - -1.76 -0.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 25.00%

more financials information »

Pluristem Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PSTI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year1.512.210.951.70162,404-0.51-33.77%
3 Years3.7513.500.955.85666,488-2.75-73.33%
5 Years15.1016.000.956.86510,629-14.10-93.38%

Pluristem Therapeutics Description

Pluristem Therapeutics Inc is a US-based company that acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The lead indications are critical limb ischemia, recovery after surgery for femoral neck fracture, and acute radiation syndrome. The company operations are focused on the research, development, clinical trials, and manufacturing of cell therapeutics and related technologies.